A subsequent study confirmed this hypothesis, demonstrating that FABP4 small-molecule inhibitors were effective in treating severe atherosclerosis and T2D in mouse experimental models (Furuhashi et al., 2007), suggesting that chemical inhibition of FABP4 could also be utilized to produce beneficial effects in human diabetes and cardiovascular disease. This evidence concerns the gene FABP4 and cardiovascular disorder.